Effects of alloporinol in prevention of contrast induced nephropathy in patients undergoing angioplasty

Abstract

Contrast-induced nephropathy (CIN) is a known complication of angiographic procedures which is the third leading cause of hospitalization; Therefore, it needs treatment and prevention. Alloprinol is a cheap and tolerable drug and is considered as a new treatment method to prevent CIN in patients at high risk of kidney disease. Therefore, in this study, we intend to investigate the effect of alloprinol in preventing CIN in patients undergoing angioplasty. Materials and Methods: This randomized clinical trial study was performed with the participation of 100 patients (50 in the control group and 50 in the intervention group) angiography candidates in Shahid Madani Hospital (Tabriz-Iran). After randomly assigning patients to the two groups, the intervention was started. For the intervention group, allopurinol tablets were given at a dose of 300 mg the day before angiography and then 300 mg exactly one hour before angiography and the control group was given placebo. Creatinine levels were measured and compared before the intervention and 72 hours after the intervention. Data were compared in SPSS statistical software with t-test and Mann-Whitney U tests. Results After 72 hours of angiography, it was observed that six (12%) of the participants in the intervention group and 19 (38%) of the control group had contrast-induced nephropathy, which in this regard was between the two groups. There was a statistically significant difference (P = 0.003) in relation to the relationship between nephropathy due to our contrast demographic variables, it was found that there is no significant relationship between this complication and age, sex, blood pressure and history of heart disease (p>0/05).